| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to the field of pharmacology and represents a combination for hyperglycaemia reduction and includes at least two different somatostatin (SRIF) analogues where one SRIF analogue is octreotide while the other SRIF analogue is pasireotide; every time the active ingredients are present in the composition in free form or in the form of a pharmaceutically acceptable salt, optionally - mixed with at least one pharmaceutically acceptable for joint, separate or sequential application. n EFFECT: invention ensures reduction of the side effect caused by pasireotide ie considerable hyperglycaemia reduction. n 6 cl, 4 dwg |